bioMérieux S.A. (EPA:BIM)

Market Cap	11.72B
Revenue (ttm)	4.12B +8.3%
Net Income	377.90M -8.1%
EPS	3.17 -8.6%
Shares Out	118.07M
PE Ratio	31.33
Forward PE	20.46
Dividend	0.90 (0.88%)
Ex-Dividend Date	Jun 9, 2025

Volume	158,383
Average Volume	134,985
Open	100.60
Previous Close	102.00
Day's Range	97.95 - 100.60
52-Week Range	97.95 - 128.30
Beta	0.68
RSI	25.19
Earnings Date	Feb 27, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.